Obstructive Sleep Apnea: A Systemic Disease
View Published Articles →01About This Special Issue
Obstructive sleep apnea syndrome (OSAS) is a highly prevalent sleep disorder, characterized by repeated disruptions of breathing during sleep. This disease has many potential consequences including excessive daytime sleepiness, neurocognitive deterioration, endocrinologic and metabolic effects, and decreased quality of life. Metabolic syndrome is another highly prevalence emerging public health problem that represents a constellation of cardiovascular risk factors. Each single component of the cluster increases the cardiovascular risk, but the combination of factors is much more significant. It has been suggested that the presence of OSAS may increase the risk of developing some metabolic syndrome features. Moreover, OSAS patients are at an increased risk for vascular events, which represent the greatest morbidity and mortality of all associated complications.Although the etiology of OSAS is uncertain, intense local and systemic inflammation is present. A variety of phenomena are implicated in this disease such as modifications in the autonomic nervous system, hypoxemia–reoxygenation cycles, inflammation, and coagulation–fibrinolysis imbalance. OSAS patients also present increased levels of certain biomarkers linked to endocrine-metabolic and cardiovascular alterations among other systemic consequences.
The Aim of this Special issue is to clarify that OSAS is more than a local abnormality, and it should be considered a systemic disease.
02Meet the Guest Editors
Our distinguished editors bring deep subject-matter expertise to curate high-quality research and ensure a rigorous peer-review process.
Lead Guest Editor
Aliae AR Mohamed-Hussein
Chest Department, Assiut University Hospitals, Assiut, Egypt
Guest Editor
Jafar Al-Sharab
Northwestern State University, Las Vegas, United States
Guest Editor
Obair Siddiqui
LG Electronics Inc., Detroit, United States
Guest Editor
Klaus Dulhoff
Pulmonology Department, Medical University of Lubeck, Lubeck, Germany
Guest Editor
Tenor Henning Koth
Pulmonology Department, Medical University of Lubeck, Lubeck, Germany
Guest Editor
Andreas Rembert Koczulla
Pulmonology Department, Marburg University, Marburg, Germany
Guest Editor
Roland Buhl
Pulmonary Department, Mainz University Hospital, Mainz, Germany
Guest Editor
Hossam Gendi
Essex Cardiac Center, Princess Alexandra Hospital, London, United Kingdom
Guest Editor
John Moxham
Physiology Department, Kings College London, London, United Kingdom
Guest Editor
Micheal Polkey
Physiology Department, Imperial College London, London, United Kingdom
Guest Editor
Yoshino Ichiro
Pulmonology Department, Chiba University, Chiba, Japan
Guest Editor
Mohammed Obeidat
Jordan University of Science and Technology, Amman, Jordan
Guest Editor
Sherifa Hamed
Department of Neurology and Psychiatry, Assiut University Hospital, Assiut, Egypt
Guest Editor
Ayman Khairy
Cardiology Department, Assiut University Hospitals, Assiut, Egypt
03Published Articles
The following articles have been published in this special issue.
-
Sleep Related Conditions with Myasthenia Gravis: Evidence, Causes and Implications
Issue: Volume 4, Issue 2-1, April 2016Pages: 6-16Received: 15 August 2015Accepted: 17 August 2015Published: 8 September 2015Abstract: Myasthenia gravis (MG) is an autoimmune disease caused mainly by antibodies against skeletal muscle nicotinic acetylcholine receptors (nAChRs) at the postsynaptic membrane resulting in depletion of acetylcholine at the neuromuscular junction (NMJ). Muscle fatigue is the cardinal symptom of MG. Respiratory muscle weakness and breathing problems are ... Show More -
Obstructive Sleep Apnoea: Another Burden on Cirrhotic Liver
Issue: Volume 4, Issue 2-1, April 2016Pages: 1-5Received: 4 July 2015Accepted: 6 July 2015Published: 8 September 2015Abstract: Obstructive sleep apnea syndrome (OSAS) may cause aggressive deterioration in the course of liver cirrhosis and may have an impact on the development of hepatic cell failure in patients with concomitant diseases. Patients and Methods: 34 patients with OSAS and compensated cirrhosis as well as 30 compensated cirrhotic patients were followed for 1 ye... Show More
